Xyzal and Infusion site rash - a phase IV clinical study of FDA data

Summary:

Infusion site rash is reported as a side effect among people who take Xyzal (levocetirizine dihydrochloride), especially for people who are male, 60+ old, also take Prednisone, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site rash when taking Xyzal. It is created by eHealthMe based on reports of 20,548 people who have side effects when taking Xyzal from the FDA, and is updated regularly.

What is Xyzal?

Xyzal has active ingredients of levocetirizine dihydrochloride. It is often used in allergies. eHealthMe is studying from 21,479 Xyzal users. Check the latest studies of Xyzal.

What is Infusion site rash?

Infusion site rash is found to be associated with 234 drugs and 153 conditions by eHealthMe. Check the latest studies of Infusion site rash.

On Jul, 09, 2026

20,548 people reported to have side effects when taking Xyzal.
Among them, 19 people (0.09%) have Infusion site rash.

Among these 19 people:

What is the gender of people who have Infusion site rash when taking Xyzal? *

female: 42.11 %
male: 57.89 %

What is the age of people who have Infusion site rash when taking Xyzal? *

What are other drugs people take besides Xyzal? *

What are other side effects people have besides Infusion site rash? *

Infusion Site Pruritus (severe itching at infusion site): 12 people, 63.16%
Headache (pain in head): 9 people, 47.37%
Cough: 8 people, 42.11%
Infusion Site Erythema (reddening of the skin at infusion site): 8 people, 42.11%
Foot Fracture: 8 people, 42.11%
Infusion Site Swelling: 7 people, 36.84%
Rhinorrhea (watery mucus discharge from the nose): 6 people, 31.58%
Nausea And Vomiting: 6 people, 31.58%
Arrhythmias (irregular heartbeat): 6 people, 31.58%
Oxygen Saturation Decreased: 6 people, 31.58%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 9 people, 47.37%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 21.05%
Primary Immunodeficiency Syndrome: 2 people, 10.53%
Portopulmonary Hypertension (coexistence of portal and pulmonary hypertension): 2 people, 10.53%
Parkinson's Disease: 2 people, 10.53%
Asthma: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Xyzal and have Infusion site rash?

- Check whether Infusion site rash is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xyzal:

Xyzal (21,479 reports)

Infusion site rash treatments and more:

Infusion site rash (1,454 reports)

How severe was Infusion site rash and when was it recovered:

Infusion site rash in Xyzal

Expand to all the drugs that have ingredients of levocetirizine dihydrochloride:

Infusion site rash and drugs with ingredients of levocetirizine dihydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xyzal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site rash:

Infusion site rash (234 drugs)

Browse all the conditions that are associated with Infusion site rash:

Infusion site rash (153 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on levocetirizine dihydrochloride (the active ingredients of Xyzal) and Xyzal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.